Home › Funds › Candriam S.C.A. › JNJ

Candriam S.C.A. position in JNJ

JOHNSON & JOHNSON · Health Care

Candriam S.C.A. reported holding 516,642 shares of JNJ (JOHNSON & JOHNSON) in its Q3 2026 13F filing — a position valued at US$137.3M, representing 0.62% of its reported portfolio and ranking #31 among its reported holdings. Candriam S.C.A. has disclosed JNJ holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)516.64K sh
Reported value held$137.28M
Portfolio Weight0.62%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Candriam S.C.A.'s JNJ position evolved

Candriam S.C.A. first disclosed a stake in JNJ in Q3 2023 at 486,908 shares (US$75.8M). The position peaked in Q1 2026 at 798,815 shares, worth US$195.3M. Across 13 filings, Candriam S.C.A. increased the stake 7 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 516,642 shares valued at US$137.3M — an increase of 6,468 shares quarter over quarter.. Notable position changes include a 37% trim in Q4 2023 (shares rose 1% over the following quarter), a 115% increase in Q3 2025 (shares rose 11% over the following quarter), a 36% trim in Q2 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 486.91K $75.84M New
Q4 2023 307.23K $48.16M Reduce
Q1 2024 273.50K $43.26M Reduce
Q2 2024 280.24K $40.96M Add
Q3 2024 265.15K $42.97M Reduce
Q4 2024 277.05K $40.07M Add
Q1 2025 299.11K $49.61M Add
Q2 2025 295.67K $45.17M Reduce
Q3 2025 636.02K $117.93M Add
Q4 2025 749.60K $155.14M Add
Q1 2026 798.82K $195.26M Add
Q2 2026 510.17K $129.44M Reduce
Q3 2026 516.64K $137.28M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JNJ and 13F data

JNJ (JOHNSON & JOHNSON) is a Health Care company. 32 other funds we track also report a position in JNJ — the largest reported positions include BlackRock Inc (US$53.87B), Vanguard Group (US$49.74B), VANGUARD CAPITAL MANAGEMENT LLC (US$41.76B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JNJ

All JNJ fund holders →

FAQ

How long has Candriam S.C.A. held JNJ?

Candriam S.C.A. has disclosed JNJ holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Candriam S.C.A.'s current position in JNJ?

As of Q3 2026, Candriam S.C.A. holds 516.64K shares of JNJ (JOHNSON & JOHNSON), valued at $137.28M, representing 0.62% of its reported portfolio and ranking #31.

Has Candriam S.C.A. been buying or selling JNJ?

In the latest 13F filing (Q3 2026), Candriam S.C.A. increased its position in JNJ. The position peaked in Q1 2026 at 798.82K shares.

Which other funds hold JNJ?

Other major institutional holders of JNJ include BlackRock Inc, Vanguard Group, VANGUARD CAPITAL MANAGEMENT LLC, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.